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Abstract 
Article History 
 
The present investigation is aimed at developing the stability indicating dissolution media for 
the determination of didanosine (DDI, a HIV-1 Reverse Transcriptase inhibitor) in 
pharmaceutical dosage forms for the first time. The stability of didanosine was tested in 
various dissolution media, ie., 0.1M HCl, pH 1.2 KCl-HCl buffer and pH 5.8, 6.2, 6.6, 7.0, 7.4 
and 7.8 phosphate buffers separately. The stability was tested at room temperature and 
37oC for 48 hrs. The samples were scanned for stability and the optimized samples were 
selected for further study. Stability studies of DDI in various media at RT and 37oC indicated 
that the drug is stable in pH 1.2 KCl-HCl buffer, pH 6.2 and pH 7.0 phosphate buffers in the 
UV region for a period of 48 hr. The λmax were found to be 248.4, 249.3 and 254.4 nm for pH 
1.2 KCl-HCl buffer, pH 6.2 and pH 7.0 phosphate buffers respectively with observed low 
coefficient of variation of <2.81%. Standard graphs were constructed in the above three 
media and linearity of the graphs were found to be in the range of 0.2-60, 0.2-40 and 0.5 – 
40 µg/ml in pH 1.2 KCl-HCl buffer, pH 6.2 and pH 7.0 phosphate buffers respectively. The 
methods were validated and found to be precise, accurate and robust. These methods can 
be used for routine assay of DID in various dosage forms. In-vitro dissolution testing 
indicated that the drugs are stable and drug release is uniform for all dosage forms. It is 
concluded that the three optimized media could be used as dissolution media as simulated 
gastric fluid (pH 1.2 KCl-HCl buffer) and simulated intestinal fluids (pH 6.2 and pH 7.0 
phosphate buffers) to study the dissolution profiles of DDI. Further these methods can be 
extended to bioequivalence studies of newly developed formulations of DID in the selected 
liquid media for both conventional and extended release dosage forms. 
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Introduction 
Dissolution medium is used for the regular in-vitro 
determination of various drugs. It is often desirable to have a 
dissolution medium that is stable and selective based on the 
formulation used. In light of the FDA's recent guidance there is 
an increased awareness of the potential relevance of 
dissolution tests [1, 2]. The FDA provides guidelines for 
dissolution tests for oral modified release dosage forms, but 
also realizes the need for individualizing the method on a case 
by case basis leaving the justification of a given methodology 
up to the scientist. As a result of patent expiry for many drugs, 
there is increase in rise of formulating the dosage forms from 
conventional to extended release products. The draft proposal 
of International Pharmacopoeia mentions methanol as 
dissolution fluid and recommends to develop a suitable 
dissolution medium for DID tablets and capsules [3, 4]. 
Therefore there is a tremendous scope for pharmaceutical 
scientist to develop suitable dissolution testing media for 
bioequivalence studies of newly developed formulations. 
Didanosine (DID) is chemically, 9-[5-(hydroxymethyl)oxolan-2-
yl]-3H-purin-6-one, is a  antiretroviral drug acts by inhibiting 
HIV-1 Reverse Transcriptase enzyme [5]. DID was selected as 
drug in the present study because more varieties of generic 
formulations are coming up in the market both as conventional 
and extended release dosage forms. The present investigation 
is aimed at developing the stability indicating dissolution media 
for the determination of didanosine in pharmaceutical dosage 
forms such as conventional and extended release tablets. 
 
 
 
 
 
 
 
 
 
 
 
9-[5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one 
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Materials and Methods 
Materials 
Pure samples of Didanosine was obtained as gratis 
sample from Matrix Laboratories, Hyderabad, India. Potassium 
dihydrogen phosphate of AR grade and other chemicals of AR 
grade were purchased from E. Merck® (India) Ltd., Mumbai. 
Water used was triple distilled grade and prepared by all glass 
distillation apparatus (quartz distillation unit, Borosil®). 
Formulations of didanosine (Dinex-Brand 1, Dinosin-Brand 2 
and Virosine-Brand 3) were purchased from local Indian 
market. 
Stability studies 
Nine dissolution media were selected and prepared such 
as distilled water, 0.1M HCl, pH 1.2 KCl-HCl buffer and pH 5.8, 
6.2, 6.6, 7.0, 7.4 and 7.8 phosphate buffers as per the 
standards of USP [6]. The pH of the buffers was measured and 
adjusted using pH Analyzer (Elico®, Model No. LI612). Stock 
solutions of didanosine (DDI) were prepared by dissolving 
accurately weighed (Afcoset® electronic balance) 25 mg of DDI 
in 25 mL of distilled water,  0.1M HCl, pH 1.2 KCl-HCl buffer 
and pH 5.8, 6.2, 6.6, 7.0, 7.4 and 7.8 phosphate buffers 
separately to obtain 1mg/mL solutions. All the solutions were 
sonicated using ultrasonic bath (Enertech®) to dissolve the 
drug. From these solutions 2.5 mL was pipetted out (Genie® 
micropipettes) into 25 mL volumetric flask and diluted with the 
same solvent system to obtain 100 µg/mL solutions. The 
stability of 100 µg/mL solutions of didanosine was tested in the 
above prepared dissolution media at room temperature (RT) 
and 37oC in an incubator (Thermolab®) for 48 hrs separately. 
Two sets of these solutions are prepared and maintained at RT 
and 37oC in an incubator. All the samples were centrifuged 
(Remi®) for 5 min before scanning. The samples were scanned 
at 0, 24 and 48 hr intervals using a double-beam UV-visible 
spectrophotometer (Elico®, India, model SL 169) connected to 
computer loaded with Spectral Treats® software. The λmax and 
absorbances were measured to verify any deviations in the 
values. The above procedure is followed for all the media. The 
dissolution media that have shown stability of the drug were 
selected for further evaluation.  
Development and validation of analytical methods  
Standard graphs of DID were constructed for the selected 
dissolution media after optimizing the conditions based on 
stability studies. Absorbances were determined for DDI at 
selected λmax values using UV-visible spectrophotometer 
(Elico®, India, model SL 169) for each of the above selected 
stable media after making dilutions to obtain 0.1 – 100 µg/mL 
concentrations from the stock solutions. The beer’s limit was 
determined from the constructed plots of wavelength vs 
absorbance. The proposed methods were validated for 
accuracy, precision and robustness. The methods were tested 
for intra-day and inter-day variations. The recovery studies 
were carried out by adding known amounts of (10 µg and 20 
µg) of DDI to the pre-analyzed samples and subjecting them to 
the proposed UV spectrophotometric methods. Replicates of 
six samples were tested for the above studies. 
Assay of didanosine in commercial formulations  
The estimation of drug content in commercial formulations 
was carried out in the developed analytical methods using 
selected dissolution media. Contents of ten tablets containing 
DDI were pooled and powdered. The powder equivalent to 25 
mg of DDI was extracted into selected medium and the volume 
was adjusted to 25 mL, mixed by sonication and filtered 
through a 0.45 µm Whatnam filter paper. From the filtrate 0.1 
mL was pipetted into a 10 mL graduated test tube and then the 
volume was adjusted to 10 mL with the dissolution medium 
and was assayed for DDI content using selected methods. The 
above procedure was followed for remaining tablet brands and 
for all the selected methods in replicates of six. 
In-vitro dissolution rate testing  
The in-vitro test was conducted to verify the stability of 
DID in the optimized and selected dissolution media during the 
dissolution testing. 
The dissolution testing was carried out in a six-stage 
dissolution rate testing apparatus USP XXI (Labindia, 
Mumbai). A 900ml of the selected dissolution medium was 
taken separately and dissolution test was performed using 
paddle method at 37oC and 75 rpm. Aliquot volumes of 5ml 
each were withdrawn from the dissolution bowl at various time 
intervals, i.e., 5, 10, 15, 20, 30, 35, 45, 60, 90 and 120 min. 
The samples were replaced by equal volume of media and 
analyzed at selected λmax using UV-visible spectrophotometer 
(Elico®, India, model SL 169) against blank solution containing 
dissolution medium after suitable dilution. The dissolution test 
was performed on the tablets of Brand 1 employing the 
selected dissolution media. 
Results and Discussion 
The stability of 100 µg/mL solutions of didanosine was 
successfully tested in nine dissolution media such as distilled 
water, 0.1M HCl, pH 1.2 KCl-HCl buffer and pH 5.8, 6.2, 6.6, 
7.0, 7.4 and 7.8 phosphate buffers as per the standards of IP 
maintained at RT and 37oC for 48 hrs separately. Stability 
studies of DDI in various media at RT and 37oC indicated that 
the drug is stable in pH 1.2 KCl-HCl buffer, pH 6.2 and pH 7.0 
phosphate buffers in the UV region for a period of 48 hr. The 
results are summarized in Table 1 and Figures 1-3. The λmax 
were found to be 248.4, 249.3 and 254.4 nm for pH 1.2 KCl-
HCl buffer, pH 6.2 and pH 7.0 phosphate buffers respectively 
with observed low coefficient of variation of <2.81%. The 
analytical methods for DID in the three selected dissolution 
media were developed and named as method A, B and C for 
pH 1.2 KCl-HCl buffer, pH 6.2 and pH 7.0 phosphate buffers 
respectively. The selected dissolution media were used to 
develop analytical methods for DID and denoted as methods 
A, B and C for pH 1.2 KCl-HCl buffer, pH 6.2 and pH 7.0 
phosphate buffers respectively. Standard graphs were 
constructed in the above three media and linearity of the 
graphs were found to be in the range of 0.2-60, 0.2-40 and 0.5-
40 µg/ml in pH 1.2 KCl-HCl buffer, pH 6.2 and pH 7.0 
phosphate buffers respectively. The regression equations from 
calibration graphs were found to be y = 0.026x + 0.0115 (R2 = 
0.9995), y = 0.0478x + 0.0117 (R2 = 0.9995) and y = 0.0467x + 
0.0055 (R2 = 0.9994) for pH 1.2 KCl-HCl buffer (method A), pH 
6.2 phosphate buffer (method B) and pH 7.0 phosphate buffer 
(method C) respectively. The optical characteristics and 
regression analysis of proposed analytical methods in selected 
dissolution media were summarized in Table 2. The methods 
were validated for precision, accuracy and robustness. The 
variation for intra-day analysis was <1.87% and for inter-day 
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analysis was <2.31% which indicates that the proposed 
methods were precise (Table 3). Mean recovery of DID using 
the developed methods was in the range of 99.91-100.05 
(Table 4) showed that the methods were accurate. The 
methods were validated and found to be precise, accurate and 
robust. Assay of three brands of DID was determined using the 
developed methods. The mean amount of DID determined was 
98.9-101.24, 99.79-100.02 and 99.55-100.16 for the developed 
methods A, B and C respectively. 
The in-vitro test was conducted to verify the stability of DID 
in the optimized and selected dissolution media during the 
dissolution testing. The dissolution test was performed on the 
tablets of Brand 1 employing the three dissolution media which 
were optimized. In-vitro dissolution testing indicated that the 
drugs were stable in pH 1.2 KCl-HCl buffer, pH 6.2 and pH 7.0 
phosphate buffers and drug release was uniform for all dosage 
forms (Figure 4). The results show that the optimized dissolution 
media can be employed to conduct dissolution testing of DID 
tablets.
 
Table 1. Stability of Didanosine in various media at 37 oC 
Values in parenthesis are ±standard deviation (n=6). 
a%CV = percent coefficient of variation of absorbances of 0, 24 and 48 hrs  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Scanning curves of didanosine in pH 1.2 acid buffer at time intervals of 0, 24 and 48 hrs and temperature 37 oC 
 
 
Medium 0 Hrs 24 Hrs 48 Hrs % CVa 
λmax Absorbance λmax Absorbance λmax Absorbance 
Distilled Water 250.9(±0.1) 0.592(±0.004) 250.9(±0.1) 0.669(±0.003) 250.9(±0.1) 0.731(±0.003) 10.48716 
0.1M HCl 248.6(±0.1) 0.242(±0.002) 248.4(±0.1) 0.484(±0.004) 248.4(±0.1) 0.508(±0.003) 35.77078 
pH 1.2 248.4(±0.1) 0.517(±0.002) 248.4(±0.1) 0.516(±0.006) 248.4(±0.1) 0.513(±0.004) 0.403946 
pH 5.8 249.4(±0.1) 0.607(±0.004) 249.5(±0.1) 0.621(±0.004) 249.4(±0.1) 0.652(±0.005) 3.674835 
pH 6.2 249.4(±0.1) 0.870(±0.003) 249.3(±0.1) 0.908(±0.002) 249.3(±0.1) 0.918(±0.002) 2.818015 
pH 6.6 254.4(±0.1) 0.547(±0.006) 254.3(±0.1) 0.560(±0.004) 254.4(±0.1) 0.525(±0.004) 3.25217 
pH 7.0 254.4(±0.1) 0.524(±0.005) 254.4(±0.1) 0.529(±0.003) 254.4(±0.1) 0.542(±0.006) 1.747631 
pH 7.4 254.4(±0.1) 0.619(±0.002) 254.4(±0.1) 0.644(±0.005) 254.4(±0.1) 0.661(±0.004) 3.294169 
pH 7.8 254.7(±0.1) 0.618(±0.007) 254.7(±0.1) 0.661(±0.004) 254.7(±0.1) 0.659(±0.003) 3.756861 
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Figure 2. Scanning curves of didanosine in pH 6.2 phosphate buffer at time intervals of 0, 24 and 48 hrs and temperature 37 oC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Scanning curves of didanosine in pH 7.0 phosphate buffer at time intervals of 0, 24 and 48 hrs and temperature 37 oC 
Table 2. Optical characteristics, Regression analysis of proposed analytical methods in selected dissolution media 
Parameter Method A 
pH 1.2 
Method B 
pH 6.2 
Method C 
pH 7.0 
Optical characteristics:    
Beer’s Law limit (µg/ml) 0.2 – 60 0.2 - 40 0.5 - 40 
Sandell’s sensitivity  
(µg/cm2/0.001 absorbance unit) 
0.02181 0.020366 0.020768 
Molar Extinction coefficient  
(1 mole-1.cm-1) 
1.29 x 106 1.17 x 106 1.11 x 106 
Regression analysis:    
Slope (m) 0.026 0.0478 0.0467 
Intercept (c) 0.0115 0.0117 0.0055 
Standard error 0.013176 0.016962 0.018411 
Regression coefficient (r2) 0.9995 0.9995 0.9994 
y = mx + c, where ‘x’ is concentration in µg/ml and ‘y’ is absorbance unit. 
Table 3. Precision of the Proposed Methods 
Method Selected λmax 
(nm) 
Didanosine 
concentration 
(µg/mL) 
Concentration of didanosine (µg/ml) 
Intra-day Inter-day 
Mean (n=6) % CV Mean (n=6) % CV 
 
A 
 
248.4 
10 10.17 1.87 10.14 2.31 
30 30.09 1.36 30.12 2.11 
 
B 
 
249.3 
10 10.11 1.61 10.05 1.89 
30 30.14 1.13 30.09 1.95 
 
C 
 
254.4 
10 10.09 1.76 10.10 1.99 
30 30.07 1.64 30.14 2.26 
%CV = percent coefficient of variation  
Prakash Katakam et al./Rec Res Sci Tech 3 (2011) 41-45 
 
  
 45
Table 4. Recovery studies of didanosine 
Method Selected λmax (nm) Amount of drug added 
(µg) 
Mean (±s.d.) amount 
(µg) found (n=6) 
Mean % recovery 
 
A 
 
248.4 
10 9.996 (±0.06) 99.92 
20 20.015 (±0.08) 100.05 
 
B 
 
249.3 
10 10.022 (±0.04) 100.02 
20 19.955 (±0.06) 99.91 
 
C 
 
254.4 
10 10.016 (±0.03) 100.01 
20 20.008 ±0.09) 100.04 
Table 5. Assay of different Brands of Didanosine tablets 
Method Brand Labeled amount of 
drug (mg) 
Mean % of labeled  
amount (n=6) 
%CV 
 
A 
Brand 1 100 101.24 2.84 
Brand 2 100 99.84 1.76 
Brand 3 250 98.9 2.49 
 
B 
Brand 1 100 99.79 2.72 
Brand 2 100 99.81 2.16 
Brand 3 250 100.02 1.98 
 
C 
Brand 1 100 100.16 2.51 
Brand 2 100 100.09 2.36 
Brand 3 250 99.55 1.99 
%CV= percent coefficient of variation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Cumulative % of DID released vs time plots in pH 1.2 KCl-HCl buffer ( –♦– ),  
pH 6.2 phosphate buffer (–■–) and pH 7.0 phosphate buffer (–▲– ). 
 
Conclusions 
It is concluded that the three stable liquid media were 
optimized for the first time. Analytical methods using optimized 
media were developed and they can be used for routine assay 
of DID in various dosage forms. The developed dissolution 
media could be employed as simulated gastric fluid (pH 1.2 
KCl-HCl buffer) and simulated intestinal fluids (pH 6.2 and pH 
7.0 phosphate buffers) to study the in-vitro dissolution profiles 
of tablets of DDI. Further these methods can be extended to 
bioequivalence studies of newly developed formulations of DID 
in the selected liquid media for both conventional and extended 
release dosage forms. 
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